[HTML][HTML] Impact of GLP-1 receptor agonists in gastrointestinal endoscopy: an updated review
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have become one of the most
popular medications for patients with diabetes and obesity. Due to their effects on gut motility …
popular medications for patients with diabetes and obesity. Due to their effects on gut motility …
GLP-1 and IL-6 regulates obesity in the gut and brain
K Yang, Y Wu, Y He, J Dai, Y Luo, J Xie, W Ding - Life Sciences, 2024 - Elsevier
Obesity is a chronic metabolic disease characterized by excessive nutrient intake leading to
increased subcutaneous or visceral fat, resulting in pathological and physiological changes …
increased subcutaneous or visceral fat, resulting in pathological and physiological changes …
Rome Foundation and international neurogastroenterology and motility societies' consensus on idiopathic gastroparesis
J Schol, IH Huang, F Carbone… - The Lancet …, 2025 - thelancet.com
To establish a consensus on the definition and management of idiopathic gastroparesis,
international experts (selected by neurogastroenterology and motility societies and initiated …
international experts (selected by neurogastroenterology and motility societies and initiated …
Glucagonlike peptide-1 receptor agonists: the good, the bad, and the ugly—benefits for glucose control and weight loss with side effects of delaying gastric emptying
HP Parkman, DS Rim, JR Anolik… - Journal of Nuclear …, 2024 - Soc Nuclear Med
Glucagonlike peptide-1 (GLP-1) receptor agonists (RAs) are being increasingly used for
glycemic control in patients with diabetes and for weight loss and weight management in …
glycemic control in patients with diabetes and for weight loss and weight management in …
Common postbariatric surgery emergencies for the acute care surgeon: What you need to know
V Cheng, K Samakar, AB Dobrowolsky… - Journal of Trauma …, 2023 - journals.lww.com
The field of bariatric and metabolic surgery has changed rapidly over the past two decades,
with an exponential increase in case volumes being performed because of its proven …
with an exponential increase in case volumes being performed because of its proven …
Aspiration under anesthesia: what happens after we sound the glucagon-like peptide-1 receptor agonist alarm?
J Bartoszko, W van Klei - … Journal of Anesthesia/Journal canadien d' …, 2024 - Springer
Canonical knowledge in anesthesiology, passed from generations of attending physicians to
residents, identifies several comorbidities associated with an increased risk of aspiration …
residents, identifies several comorbidities associated with an increased risk of aspiration …
[HTML][HTML] Tendency of Semaglutide to Induce Gastroparesis: A Case Report
A Chaudhry, B Gabriel, J Noor, S Jawad, SR Challa - Cureus, 2024 - ncbi.nlm.nih.gov
Semaglutide, an agonist of the glucagon-like peptide-1 receptor, is frequently used in the
treatment of diabetes mellitus type 2, although, lately, weight loss has additionally become a …
treatment of diabetes mellitus type 2, although, lately, weight loss has additionally become a …
Tendency of Semaglutide to Induce Gastroparesis: A Case Report
C Ahtshamullah, G Buluku, N Jawad, J Saima… - Cureus, 2024 - search.proquest.com
Semaglutide, an agonist of the glucagon-like peptide-1 receptor, is frequently used in the
treatment of diabetes mellitus type 2, although, lately, weight loss has additionally become a …
treatment of diabetes mellitus type 2, although, lately, weight loss has additionally become a …
Mechanisms underlying monosaccharide stimulated incretin hormone secretion from the intestine
E O'Flaherty Rottenberger - 2024 - repository.cam.ac.uk
Obesity and type II diabetes (T2D) are healthcare crises with continually rising prevalence
worldwide. Drugs which mimic the gut hormone glucagon-like peptide-1 (GLP-1), eg …
worldwide. Drugs which mimic the gut hormone glucagon-like peptide-1 (GLP-1), eg …